Table 1.
Study | Study design | n ∗ | AD vs. controls |
---|---|---|---|
(i) Myeloperoxidase | |||
Tzikas et al. [39] | Cross-sectional | 55 | ↑ |
Cheng et al. [40] | Cross-sectional | 199 | ↑ |
Marksteiner et al. [41] | Cross-sectional | 56 | ↔ |
Wu et al. [42] | Cross-sectional | 170 | ↔ |
(ii) Serum amyloid A | |||
Cao and Chen [44] | Cross-sectional | 352 | ↑ |
Shang et al. [45] | Cross-sectional | 673 | ↑ |
Kindy et al. (CSF) [16] | Cross-sectional | 31 | ↑ |
(iii) Lipoprotein phospholipase A2 | |||
van Oijen et al. [46] | Longitudinal | 6713 | ↑ |
Fitzpatrick et al. [47] | Longitudinal | 3320 | ↑ |
Bacchetti et al. [48] | Cross-sectional | 83 | ↑ |
Doody et al. [49] | Cross-sectional | 395 | ↑ |
van Himbergen et al. [50] | Longitudinal | 541 | ↔ |
(iv) Glutathione peroxidase-3 | |||
Ceballos-Picot et al. [51] | Cross-sectional | 74 | ↔ |
Serra et al. [52] | Cross-sectional | 192 | ↔ |
Puertas et al. [15] | Cross-sectional | 92 | ↓ |
Casado et al. [53] | Cross-sectional | 150 | ↓ |
Rinaldi et al. [54] | Cross-sectional | 141 | ↓ |
Vural et al. [55] | Cross-sectional | 100 | ↓ |